<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902018000400349</article-id>
<article-id pub-id-type="doi">10.29262/ram.v65i4.382</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Calidad de vida en pacientes con asma alérgica severa en tratamiento con omalizumab]]></article-title>
<article-title xml:lang="en"><![CDATA[Quality of life in patients with allergic asthma on treatment with omalizumab]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Hinojosa]]></surname>
<given-names><![CDATA[Nadia Karina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Tec]]></surname>
<given-names><![CDATA[Georgina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Regional 1 &#8220;Lic. Ignacio García Téllez&#8217; Servicio de Alergología]]></institution>
<addr-line><![CDATA[Mérida Yucatán]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Regional 1 &#8220;Lic. Ignacio García Téllez Servicio de Neumología]]></institution>
<addr-line><![CDATA[Mérida Yucatán]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<numero>4</numero>
<fpage>349</fpage>
<lpage>356</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902018000400349&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902018000400349&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902018000400349&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  El omalizumab es un anticuerpo monoclonal que controla los síntomas y reduce las exacerbaciones del asma alérgica grave.  Objetivo:  Analizar mediante el cuestionario mini-AQLQ y espirometría, la mejoría en la calidad de vida y función respiratoria con el omalizumab como complemento del tratamiento con corticosteroides inhalados y agonista beta-2 de acción prolongada.  Métodos:  De 30 pacientes con asma severa (90 % de mujeres y media de edad de 49.1 años), la evolución del diagnóstico de asma severa osciló entre uno y 24 años (promedio de 8.3 años). Todos presentaron al menos una prueba cutánea o IgE específica positiva a un aeroalérgeno, determinación de IgE total y espirometría. Al inicio y a las 52 semanas de aplicar el omalizumab (dosis promedio de 550 mg, con aplicación quincenal o mensual), se aplicó el mini-AQLQ y se obtuvo el volumen espiratorio forzado al primer segundo (VEF1).  Resultados:  Hubo mejoría significativa (p = 0.013) en el mini-AQLQ después de 52 semanas, con puntuación global de 4.5, principalmente en las dimensiones de emociones (p = 0.0073) y en la ambiental (p = 0.00014). No hubo cambios significativos del VEF1. En 63 % de los pacientes se observó obesidad y en 26 % sobrepeso.  Conclusiones:  El omalizumab mejoró la calidad de vida de los pacientes, sin cambios significativos del VEF1, probablemente por la obesidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Omalizumab is a monoclonal antibody that controls severe allergic asthma symptoms and reduces exacerbations.  Objective:  To analyze quality of life and respiratory function improvement using the mini-AQLQ questionnaire and spirometry, with the use omalizumab as complementary therapy to a treatment with inhaled corticosteroids and long-acting beta 2 agonists.  Methods:  Of 30 patients with severe asthma (90 % of females, mean age, 49.1 years) the evolution of severe asthma diagnosis ranged from 1 to 24 years (average 8.3 years). All of them had at least one cutaneous or IgE-specific test that was positive to a usual aeroallergen, had total IgE determined and underwent spirometry. The mini-AQLQ questionnaire was applied and forced expiratory volume in 1 second (FEV1) was determined at baseline and at 52 weeks of omalizumab administration, the average dose of which was 550 mg, with biweekly or monthly administration.  Results:  There was statistically significant improvement (p = 0.013) in the mini-AQLQ after 52 weeks, with an overall score of 4.5, mainly in the emotional (p = 0.0073) and environmental dimensions (p = 0.00014). There were no significant changes in FEV1. Obesity was observed in 63 % of patients, and overweight in 26 %.  Conclusions:  Omalizumab improved patient quality of life, with no significant changes in FEV1, probably due to obesity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Asma alérgica]]></kwd>
<kwd lng="es"><![CDATA[Omalizumab]]></kwd>
<kwd lng="es"><![CDATA[Calidad de vida]]></kwd>
<kwd lng="en"><![CDATA[Allergic asthma]]></kwd>
<kwd lng="en"><![CDATA[Omalizumab]]></kwd>
<kwd lng="en"><![CDATA[Quality of life]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Godard]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Daures]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The public health implications of asthma]]></article-title>
<source><![CDATA[Bull World Health Organ.]]></source>
<year>2005</year>
<volume>83</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>548-54</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas-Molina]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Legorreta-Soberanis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Olvera-Guerra]]></surname>
<given-names><![CDATA[JF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia y factores de riesgo de asma en municipios del estado de Guerrero, México]]></article-title>
<source><![CDATA[Rev Alergia Mex.]]></source>
<year>2001</year>
<volume>48</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>115-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia comparada de asma y rinitis alérgica entre niños y adultos michoacanos: escuelas públicas de Morelia]]></article-title>
<source><![CDATA[Rev Invest Clin.]]></source>
<year>2007</year>
<numero>59</numero>
<issue>59</issue>
<page-range>90-2</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas-Becerra]]></surname>
<given-names><![CDATA[MH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del asma]]></article-title>
<source><![CDATA[Neumol Cir Torax.]]></source>
<year>2009</year>
<volume>68</volume>
<page-range>91-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Global</collab>
<article-title xml:lang=""><![CDATA[Global strategy for asthma management and Prevention 2004]]></article-title>
<source><![CDATA[Global Initiative for Asthma]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kavati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vegesna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colby]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials]]></article-title>
<source><![CDATA[Curr Med Res Opin.]]></source>
<year>2018</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-80</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[SP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe asthma: an overview]]></article-title>
<source><![CDATA[J Clin Inmmunol.]]></source>
<year>2006</year>
<volume>117</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>487-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>American Thoracic Society</collab>
<article-title xml:lang=""><![CDATA[Proceedings of the ATS workshop on refractory asthma: current understanding recommendations and unanswered questions]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med.]]></source>
<year>2000</year>
<volume>162</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2341-51</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubio-Padilla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Río-Navarro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hilda]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Sienra-Monge]]></surname>
<given-names><![CDATA[JJL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asma de difícil control]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2009</year>
<volume>59</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>115-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacheco-Galván]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hinojosa-Macías]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado-Barbudo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[González-Cervera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sueiro-Bendito]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control del asma y de la calidad de vida en pacientes asmáticos alérgicos graves con tratamiento anti-IgE (omalizumab)]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2009</year>
<volume>133</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>460-3</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Brozek]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sterk]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma]]></article-title>
<source><![CDATA[Eur Respir J.]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-73</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Global Initiative for Asthma</collab>
<article-title xml:lang=""><![CDATA[Global strategy for asthma management and Prevention 2018]]></article-title>
<source><![CDATA[Global Initiative for Asthma]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics, definition and phenotypes of severe asthma]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[: Chung]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Bel]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[Difficult to treat severe asthma]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Reino Unido ]]></publisher-loc>
<publisher-name><![CDATA[European Respiratory Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKeage]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab: a review of its use in patients with severe persistent allergic asthma]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2010</year>
<volume>73</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1197-212</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vennera-Trunzo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab: estudios clínicos y en la &#8220;vida real&#8221; para el tratamiento del asma bronquial]]></article-title>
<source><![CDATA[Monogr Arch Bronconeumol.]]></source>
<year>2015</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>92-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chipps]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Buhl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Beeh]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Reisner]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement in quality of life with omalizumab in patients with severe allergic asthma]]></article-title>
<source><![CDATA[Curr Med Res Opin.]]></source>
<year>2006</year>
<volume>22</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2201-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Souza-Machado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade-Lima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Honda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of omalizumab as add-on therapy on asthma-related quality of life on severe allergic asthma: a Brazilian study (QUALITX)]]></article-title>
<source><![CDATA[J Asthma]]></source>
<year>2012</year>
<volume>49</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>288-93</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Méndez-Guerra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salas-Hernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Chavira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[León-Munguía]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Franco-Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida en pacientes asmáticos mexicanos.]]></article-title>
<source><![CDATA[Rev Inst Nal Enf Resp Mex.]]></source>
<year>2003</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>235-42</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas-Correa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bracamonte-Peraza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Morales]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez-Nava]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia clínica con omalizumab en pacientes con asma severa. Datos del mundo real]]></article-title>
<source><![CDATA[Rev Alerg Mex.]]></source>
<year>2016</year>
<volume>63</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>216-26</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niven]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Panahloo]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ayre]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study]]></article-title>
<source><![CDATA[Resp Med.]]></source>
<year>2008</year>
<volume>102</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1371-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
